[PDF][PDF] Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study
T Ishida, T Joh, N Uike, K Yamamoto, A Utsunomiya… - J Clin …, 2012 - researchgate.net
T Ishida, T Joh, N Uike, K Yamamoto, A Utsunomiya, S Yoshida, Y Saburi, T Miyamoto…
J Clin Oncol, 2012•researchgate.netPurpose Adult T-cell leukemia-lymphoma (ATL) is usually resistant to conventional
chemotherapies, and there are few other treatment options. Because CC chemokine
receptor 4 (CCR4) is expressed on tumor cells from most patients with ATL, KW-0761, a
humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent
cellular cytotoxicity, was evaluated in the treatment of patients with relapsed ATL.
chemotherapies, and there are few other treatment options. Because CC chemokine
receptor 4 (CCR4) is expressed on tumor cells from most patients with ATL, KW-0761, a
humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent
cellular cytotoxicity, was evaluated in the treatment of patients with relapsed ATL.
Purpose
Adult T-cell leukemia-lymphoma (ATL) is usually resistant to conventional chemotherapies, and there are few other treatment options. Because CC chemokine receptor 4 (CCR4) is expressed on tumor cells from most patients with ATL, KW-0761, a humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent cellular cytotoxicity, was evaluated in the treatment of patients with relapsed ATL.
researchgate.net